Show simple item record

dc.contributor.authorSakai, Yu
dc.contributor.authorCao, Quy
dc.contributor.authorRubin, Jeremy
dc.contributor.authorWitsch, Jens
dc.contributor.authorCohen‐Addad, Dan
dc.contributor.authorde Macedo Rodrigues, Katyucia
dc.contributor.authorCoco Martín, María Begoña
dc.contributor.authorPasyar, Pouyan
dc.contributor.authorJuega, Jesús
dc.contributor.authorFan, Zhaoyang
dc.contributor.authorKasner, Scott E.
dc.contributor.authorCucchiara, Brett L.
dc.contributor.authorSong, Jae W.
dc.date.accessioned2024-01-11T11:23:32Z
dc.date.available2024-01-11T11:23:32Z
dc.date.issued2023
dc.identifier.citationJ Am Heart Assoc. 2023 Dec 5;12(23)es
dc.identifier.issn2047-9980es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/64440
dc.descriptionProducción Científicaes
dc.description.abstractBACKGROUND: Complex aortic plaque (CAP) is a potential embolic source in patients with cryptogenic stroke (CS). We review CAP imaging criteria for transesophageal echocardiogram (TEE), computed tomography angiography (CTA), and magnetic resonance imaging and calculate CAP prevalence in patients with acute CS. METHODS AND RESULTS: PubMed and EMBASE databases were searched up to December 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Two independent reviewers extracted data on study design, imaging techniques, CAP criteria, and prevalence. The Cochrane Collaboration tool and Guideline for Reporting Reliability and Agreement Studies were used to assess risk of bias and reporting completeness, respectively. From 2293 studies, 45 were reviewed for CAP imaging biomarker criteria in patients with acute CS (N=37 TEE; N=9 CTA; N=6 magnetic resonance imaging). Most studies (74%) used ≥4 mm plaque thickness as the imaging criterion for CAP although ≥1 mm (N=1, CTA), ≥5 mm (N=5, TEE), and ≥6 mm (N=2, CTA) were also reported. Additional features included mobility, ulceration, thrombus, protrusions, and assessment of plaque composition. From 23 prospective studies, CAP was detected in 960 of 2778 patients with CS (0.32 [95% CI, 0.24–0.41], I2=94%). By modality, prevalence estimates were 0.29 (95% CI, 0.20–0.40; I2=95%) for TEE; 0.23 (95% CI, 0.15–0.34; I2=87%) for CTA and 0.22 (95% CI, 0.06–0.54; I2=92%) for magnetic resonance imaging. CONCLUSIONS: TEE was commonly used to assess CAP in patients with CS. The most common CAP imaging biomarker was ≥4 mm plaque thickness. CAP was observed in one-third of patients with acute CS. However, high study heterogeneity suggests a need for reproducible imaging methods.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherAHA Journalses
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.subject.classificationaorta, atherosclerosis, biomarker, imaging, strokees
dc.titleImaging Biomarkers and Prevalence of Complex Aortic Plaque in Cryptogenic Stroke: A Systematic Reviewes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1161/JAHA.123.031797es
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue23es
dc.identifier.publicationlastpage13es
dc.identifier.publicationtitleJournal of the American Heart Associationes
dc.identifier.publicationvolume12es
dc.peerreviewedSIes
dc.identifier.essn2047-9980es
dc.rightsCC0 1.0 Universal*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record